IP Library › Patent Application 11840573
Patent Application
App. No. 11/840,573

USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/840,573
Abstract

Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).

Claims (16)

1 - 54 . (canceled)

55 . A method of treating chronic lymphocytic leukemia in a human subject comprising administering an anti-CD23 antibody and chlorambucil, wherein the anti-CD23 antibody and chlorambucil are administered simultaneously or sequentially in any order.

56 . The method of claim 55 , wherein the anti-CD23 antibody is a human, humanized, or chimeric antibody.

57 . The method of claim 56 , wherein the anti-CD23 antibody comprises a human gamma 1 heavy chain constant region.

58 . The method of claim 56 , wherein the anti-CD23 antibody comprises a human kappa light chain constant region.

59 . The method of claim 56 , wherein the anti-CD23 antibody comprises variable regions of antibody 5E8.

60 . The method of claim 59 , wherein the anti-CD23 antibody comprises human constant regions.

61 . The method of claim 60 , wherein the anti-CD23 antibody is IDEC-152.

62 . The method of claim 55 , wherein the anti-CD23 antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) of chronic lymphocytic leukemia cells.

63 . The method of claim 55 , wherein the anti-CD23 antibody induces apoptosis of chronic lymphocytic leukemia cells.

64 . The method of claim 55 , wherein the anti-CD23 antibody is capable of inhibiting the binding to CD23 of a monoclonal antibody having light chain and heavy chain variable domains of antibody 5E8.

65 . The method of claim 64 , wherein the anti-CD23 antibody comprises human constant regions.

66 . The method of claim 64 , wherein the anti-CD23 antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) of chronic lymphocytic leukemia cells.

67 . The method of claim 64 , wherein the anti-CD23 antibody induces apoptosis of chronic lymphocytic leukemia cells.

68 . The method of claim 55 , wherein the anti-CD23 antibody is conjugated to a cytotoxin.

69 . The method of claim 68 , wherein the cytotoxin is a radioisotope, a therapeutic agent, a cytostatic agent, a biological toxin, or a prodrug.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2009
From: BIOGEN IDEC INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 022602/0542 →